The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

cream or foam, for healthcare providers to choose from. ZORYVE foam allows patients to treat their whole body with one prescription, transforming the treatment landscape for scalp and body psoriasis.” ...

Menthol is extracted from mint plants, creating a cooling sensation and providing temporary relief through counter-irritation ...

the significance of the results means that patients with psoriasis of the scalp and body might want to consult their treating medical practitioner to discuss an off-label prescription for ...

“Zoryve foam allows patients to treat their whole body with one prescription ... is also available in a 0.3% cream formulation for the treatment of plaque psoriasis, including intertriginous ...

Start by applying a generous layer of an emollient — a moisturizing cream designed to ... re using a steroid or other prescription medication, the National Psoriasis Foundation (NPF) advises.